NCT02279394 2023-06-09E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaDana-Farber Cancer InstitutePhase 2 Completed51 enrolled 14 charts
NCT01441973 2018-01-23Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaBristol-Myers SquibbPhase 2 Completed41 enrolled 17 charts